Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma

British Journal of Dermatology

Volumn 164, Issue 5, 2011, Pages 1010-1016

  Lang, J ^a   Tobias, E S ^a   Mackie, R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; CHD 5 GENE; CONTROLLED STUDY; EXON; FAMILIAL CANCER; GENE LOCUS; GENE MUTATION; GENETIC LINKAGE; GENOTYPE; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MELANOMA; PATHOGENESIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

DNA HELICASES; DNA MUTATIONAL ANALYSIS; EXONS; GENES, TUMOR SUPPRESSOR; GENETIC LINKAGE; GENOTYPE; HUMANS; MELANOMA; NERVE TISSUE PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA SPLICE SITES; SKIN NEOPLASMS;

EID: 79955419660     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10223.x     Document Type: Article

References (22)

1. Mackie RM, Bray C, Vestey J, et al. Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer 2007; 96: 1772-7. (Pubitemid 46847216)
2. Hayward NK,. Genetics of melanoma predisposition. Oncogene 2003; 22: 3053-62. (Pubitemid 36713755)
3. Lang J, Boxer M, Mackie RM,. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families. Br J Dermatol 2005; 153: 1121-5. (Pubitemid 41779565)
4. Stone S, Jiang P, Dayananth P, et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995; 55: 2988-94.
5. Ruas M, Peters G,. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378: 115-77.
6. Zhang Y, Xiong Y, Yarbrough WG,. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-34. (Pubitemid 28155312)
7. Serrano M, Hannon GJ, Beach D,. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7. (Pubitemid 24036021)
8. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40.
9. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320: 1367-72. (Pubitemid 19138930)
10. Goldstein AM, Dracopoli NC, Ho EC, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 1993; 52: 537-50. (Pubitemid 23311324)
11. Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73: 301-13. (Pubitemid 36920993)
12. Dracopoli NC, Harnett P, Bale SJ, et al. Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc Natl Acad Sci USA 1989; 86: 4614-18. (Pubitemid 19164600)
13. Poetsch M, Dittberner T, Woenckhaus C,. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res 2003; 13: 29-33. (Pubitemid 36269811)
14. Bagchi A, Papazoglu C, Wu Y, et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007; 128: 459-75. (Pubitemid 46198889)
15. Smith PJ, Zhang C, Wang J, et al. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 2006; 15: 2490-508. (Pubitemid 44288702)
16. Cartegni L, Wang J, Zhu Z, et al. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568-71. (Pubitemid 37442199)
17. Ng D, Yang XR, Tucker MA, et al. Mutation screening of CHD5 in melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site changes. BMC Res Notes 2008; 19: 86-92.
18. Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008; 100: 940-9. (Pubitemid 351957513)
19. Gorringe KL, Choong DY, Williams LH, et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 2008; 10: 1253-8.
20. Lang J, Hayward N, Goldgar D, et al. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. Genes Chromosom Cancer 2007; 46: 277-87. (Pubitemid 46155322)
21. Macaya D, Katsanis SH, Hefferon TW, et al. A synonymous mutation in TCOF1 causes Treacher Collins syndrome due to mis-splicing of a constitutive exon. Am J Med Genet A 2009; 149A: 1624-7.
22. Thompson PM, Gotoh T, Kok M, et al. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003; 22: 1002-11. (Pubitemid 36313144)